Clinical Trials Browser

telapristone acetate × Clear all

NCT02314156 2023-02-22

Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy

Phase 2 Completed

67 enrolled 14 charts

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT01800422 2020-01-18

Oral CDB-4124 vs. Placebo in Stage I-II Primary Breast Cancer

Phase 2 Unknown

Breast Neoplasms

NCT02811159 2019-06-27

An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids

Phase 2 Terminated

20 enrolled 16 charts

Leiomyoma

NCT02323646 2019-06-25

Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine Fibroids

Phase 2 Completed

42 enrolled 22 charts

Fibroma, Leiomyoma

NCT02301897 2019-06-19

A Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids

Phase 2 Completed

43 enrolled 21 charts

Leiomyoma

NCT00958334 2019-06-18

Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003

Phase 2 Completed

65 enrolled 10 charts

Leiomyoma

NCT01451424 2014-08-29

Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine Fibroids

Phase 2 Completed

40 enrolled 14 charts

Leiomyoma

NCT00958893 2014-08-25

An Extension Study Evaluating Safety and Efficacy of Proellex® In Women Who Have Previously Completed ZPU 003 Ext

Phase 2 Terminated

4 enrolled 1 chart

Leiomyoma

NCT00683917 2014-08-21

Pharmacokinetics, Safety and Efficacy Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids

Phase 2 Terminated

10 enrolled 1 chart

Leiomyoma

NCT00702702 2014-08-21

Safety and Efficacy of Proellex in Pre-menopausal Anemic Women With Symptomatic Uterine Fibroids

Phase 3 Terminated

56 enrolled 1 chart

Classical hematology

Anemia, Leiomyoma

NCT00735553 2014-08-21

Evaluating the Safety and Efficacy of Proellex® (CDB-4124) in Premenopausal Women With Symptomatic Uterine Fibroids

Phase 3 Terminated

77 enrolled 1 chart

Leiomyoma

NCT00737282 2014-08-21

Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine Fibroids

Phase 3 Terminated

175 enrolled 1 chart

Leiomyoma

NCT00785356 2014-08-21

Safety and Efficacy of Proellex in Pre-Menopausal Anemic Women With Symptomatic Uterine Fibroids

Phase 3 Terminated

8 enrolled 1 chart

Classical hematology

Anemia, Leiomyoma

NCT00853567 2014-08-21

Evaluating the Safety and Efficacy of Proellex® in Premenopausal Women With Symptomatic Uterine Fibroids

Phase 3 Terminated

71 enrolled 1 chart

Leiomyoma

NCT01069120 2014-08-21

Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids

Phase 3 Terminated

27 enrolled 1 chart

Leiomyoma

NCT00882258 2014-07-08

Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids

Phase 2 Completed

Leiomyoma

NCT01069094 2014-06-30

A Study of Progenta (CDB-4124) in Pre-menopausal Women With Symptomatic Leiomyomata

Phase 1/2 Completed

Leiomyoma, Myofibroma

NCT00874302 2014-06-27

Safety and Efficacy of 25 and 50 mg Doses of Proellex® in Treating the Recurrence of Uterine Fibroid Symptoms

Phase 3 Withdrawn

Leiomyoma

NCT01631903 2014-04-16

Extension of Study ZPV-200

Phase 2 Completed

Leiomyoma

NCT01739621 2014-04-16

Safety, Pharmacokinetics and Efficacy of Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Uterine Fibroids Who Have Completed ZPV-200

Phase 2 Completed

Leiomyoma